Neuropharm Group Plc has appointed a new marketing executive to its US operating unit in preparation for the commercial launch of its treatment for autism. Chris Mario, formerly executive director of US and global marketing at Wyeth Pharmaceuticals, has been appointed ‘brand leader’ at Neuropharm Inc in Radnor, Pennsylvania.
Prior to her position with Wyeth, Ms Mario was head of US marketing for Dermik Laboratories, owned by sanofi-aventis. She has experience in brand management and launch planning across a variety of specialty product categories.
Neuropharm plans to complete its regulatory submission of its autism treatment, NPL-2008, to the Food and Drug Administration in the second quarter of 2009.
Copyright 2009 Evernow Publishing Ltd